The potential of ‘omics’ to further our understanding of cell biology and disease progression has been discussed for over 30 years, but these technologies have so far failed to translate to a healthcare setting. One of the major challenges has been the lack of reproducible results, making it difficult to distinguish between true discoveries and experimental artifacts. ProtiFi was founded to overcome these challenges: to solve the bottlenecks around sampling, sample preparation and data interpretation in order to accelerate the deployment of omics technologies in real-world clinical applications.
Proteomics studies using mass spectrometry have an important role to play in understanding tumor cell biology and the impact of novel therapeutics. Sample clean-up prior to analysis is an essential part of these workflows, and researchers at Pfizer are performing this on a positive pressure workstation to save time and enhance reproducibility.
Developing drugs that are effective, with minimal side effects, is important to improve the lives of patients suffering from serious diseases. Leading biotechnology company Amgen focuses on producing therapies for a wide range of conditions, and is currently developing small interfering RNAs (siRNAs) as a method to treat patients with a genetic predisposition to heart disease.